GCO 19-1754: Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Sep 26, 2026 - P2 | N=48 | Active, not recruiting | Sponsor: Icahn School of Medicine at Mount Sinai | Completed ➔ Active, not recruiting | Trial completion date: Aug 2025 ➔ Jul 2028
Enrollment closed • Trial completion date • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
|